From our Annual Public Meeting to topic-specific convenings, the Reagan-Udall Foundation for the FDA brings stakeholders together on matters critical to regulatory science and practice. These events, often hosted at the request of FDA leadership, provide space for expert analysis and candid discussion on FDA’s priority issues. See below for upcoming events.

Past Events

FDA’s Amy Abernethy, Friends of Cancer Research, and The Michael J. Fox Foundation for Parkinson’s Research Honored with Innovations in Regulatory Science Awards
Honorees to be recognized virtually on December 8, 2020
We may soon have a COVID-19 vaccine. But will enough people take it? - Reuters
ZURICH/LONDON (Reuters) - With COVID-19 vaccine trial results looking positive, governments and pharmaceutical firms face their next daunting challenge: convincing the world to get inoculated.
In Brief - The Cancer Letter
Reagan-Udall receives $250,000 from Rockefeller Foundation for COVID-19 Diagnostics Evidence Accelerator
Officials clarify military role in coronavirus vaccination amid wariness - Roll Call
President Donald Trump has often touted the role of the military in distributing a COVID-19 vaccine, but health officials close to the process who are concerned about public distrust are taking pains to say the federal gov
Black Americans are the most hesitant to get a COVID-19 vaccine - USA Today
Black Americans distrust the government so much they're not participating in large numbers in COVID-19 clinical trials, and many say they won't get a COVID-19 vaccine – at least not until many others get it.
Reagan-Udall Foundation for the FDA Secures New Grant from The Rockefeller Foundation for COVID-19 Diagnostics Evidence Accelerator
The Reagan-Udall Foundation for the FDA has received funding from The Rockefeller Foundation to support the COVID-19 Diagnostics Evidence Accelerator launched earlier this year in collaboration with Friends of Cancer Resea
Rushing COVID-19 Vaccination Could Undermine Overall Success, Vaccine Experts Warn FDA - IDSE
Extraordinary and unusual measures may be needed to rapidly develop and distribute a vaccine against SARS-CoV-2, but those efforts should not compromise the safety and efficacy of any product that reaches the market, accor
‘There’s only one chance to do this right’—FDA panel wrestles with COVID-19 vaccine issues - Science
Concerns raised yesterday by an advisory group to the U.S. Food and Drug Administration (FDA) may once again tap the brakes on Operation Warp Speed, the U.S.
Patient Warehousing Emerges As Another COVID-19 Vaccine Confidence Problem - Pink Sheet
Executive Summary CDC officials designing distribution plans worry some eligible for vaccination may wait for a better product to emerge.
FDA advisory committee debates safety and efficacy standards for a coronavirus vaccine - The Washington Post
Vaccine experts on Thursday rigorously debated the Food and Drug Administration’s planned standards for clearing a coronavirus vac